Physician

Allan G Coates, DO

According to 2025 Medicare claims, Allan Coates, DO (NPI: 1972510378) practices gastroenterology in the Grand Rapids-Wyoming-Kentwood, MI market, with the plurality of this provider's patient population coming from Kent, MI. This provider's primary affiliated billing organization is GASTROENTEROLOGY ASSOCIATES OF WESTERN MICHIGAN PLC (NPI: 1588731087; TIN: 382475798) and primary practice location at 49519-9691. Coates is affiliated with the POM ACO (ACO ID: A1297), West Michigan Accountable Care Organization, LLC (ACO ID: A4626), and Aledade 201 National MSSP (ACO ID: A5522), participating under the MSSP model.

Coates' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 689 traditional Medicare patients, billed 5,795 HCPCS/CPT codes, and received $267,832 in Medicare payments. The top billing code was 43249 (Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm). Part D data shows 1,620 prescription claims across 719 beneficiaries totaling $1,164,656 in drug costs, led by Stelara (Ustekinumab). 2019 DME data shows 12 claims. Open Payments data shows 140 records totaling $555,587. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $3,506,991 to $1,164,656. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,114	4,292	$380,267
2016	1,234	8,738	$490,161
2017	1,191	8,913	$464,880
2018	1,120	11,393	$504,700
2019	1,047	12,002	$535,007
2020	921	9,512	$455,718
2021	1,009	12,925	$508,932
2022	842	11,012	$402,834
2023	701	7,470	$302,728
2024	689	5,795	$267,832

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	433	2,094	$3,506,991
2016	470	2,433	$4,187,964
2017	450	2,362	$1,969,899
2018	409	2,086	$1,807,987
2019	437	2,211	$1,911,271
2020	503	2,347	$1,704,154
2021	619	2,911	$1,673,158
2022	499	2,335	$1,629,643
2023	391	1,693	$1,635,731
2024	719	1,620	$1,164,656

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	13	$302
2016	N/R	14	$287
2017	N/R	36	$1,642
2018	N/R	11	$550
2019	N/R	12	$930
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
43249	Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm	138	170	$340
45385	Removal of polyps or growths of large bowel using an endoscope with mechanical snare	104	105	$213
45380	Biopsy of large bowel using a flexible endoscope	124	125	$172
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	86	122	$85
43239	Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope	277	306	$74

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Stelara	Ustekinumab	18	1,008	$502,543
Humira(Cf) Pen	Adalimumab	45	1,456	$334,150
Creon	Lipase/Protease/Amylase	25	810	$37,986
Linzess	Linaclotide	30	1,620	$28,358
Dexlansoprazole Dr	Dexlansoprazole	33	1,530	$8,626

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	19	$344	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	121	$555,243	Takeda Pharmaceuticals U.S.A., Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Allan G. Coates, DO?

Tedicare shows public-source Medicare data for Allan G. Coates, DO (NPI 1972510378), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Allan G. Coates, DO have ACO affiliation data?

Allan G. Coates, DO is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297), West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626), and Aledade 201 National MSSP (MSSP, ACO ID A5522).

What billing organization is linked to Allan G. Coates, DO?

Allan G. Coates, DO is linked to GASTROENTEROLOGY ASSOCIATES OF WESTERN MICHIGAN PLC (billing NPI 1588731087) in the available physician profile data.

Does Allan G. Coates, DO have Open Payments data?

Allan G. Coates, DO has 140 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.